Overall Survival in EGFR-Mutant Advanced NSCLC Treated With First-Line Osimertinib: A Cohort Study Integrating Clinical and Biomarker Data in the United States
Despite advances in tyrosine kinase inhibitor treatments, long-term survival of patients with advanced EGFRm NSCLC remains poor. Nearly all patients had risk factors for mortality and one-third did not receive second-line therapy.
Authors
- Yanfang Liu (ORCID: https://orcid.org/0000-0002-0568-737X)
- Helena A. Yu (ORCID: https://orcid.org/0000-0002-0377-9510)
- Joshua K. Sabari (ORCID: https://orcid.org/0000-0002-1556-1543)
- Yen-Hua Chen
- Antonio Passaro (ORCID: https://orcid.org/0000-0002-7575-3870)
- Levon Demirdjian (ORCID: https://orcid.org/0000-0002-1854-3658)
- Parthiv J. Mahadevia
- Xiayi Wang
Institutions
- Johnson & Johnson (United States) (US)
- Memorial Sloan Kettering Cancer Center (US)
- University of San Diego (US)
- NYU Langone Health (US)
- Janssen (United States) (US)
- European Institute of Oncology (IT)
Publication Details
- Journal
- Journal of Thoracic Oncology
- Published
- 2025-05-02
- DOI
- https://doi.org/10.1016/j.jtho.2025.04.010
- Citations
- 12
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 18.22
Funders
- Johnson and Johnson